Covington Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Covington Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$60K	Hold	704	–	–	﹤0.01%	536
2022 Q2	$58K	Buy	704 +204	+41%	+$16.2K	﹤0.01%	531
2022 Q1	$39K	Hold	500	–	–	﹤0.01%	614
2021 Q4	$44K	Hold	500	–	–	﹤0.01%	568
2021 Q3	$39K	Hold	500	–	–	﹤0.01%	578
2021 Q2	$42K	Buy	500 +294	+143%	+$23.3K	﹤0.01%	560
2021 Q1	$16K	Hold	206	–	–	﹤0.01%	635
2020 Q4	$18K	Hold	206	–	–	﹤0.01%	593
2020 Q3	$16K	Hold	206	–	–	﹤0.01%	577
2020 Q2	$25K	Hold	206	–	–	﹤0.01%	522
2020 Q1	$17K	Hold	206	–	–	﹤0.01%	545
2019 Q4	$17K	Hold	206	–	–	﹤0.01%	615
2019 Q3	$14K	Hold	206	–	–	﹤0.01%	605
2019 Q2	$18K	Hold	206	–	–	﹤0.01%	566
2019 Q1	$18K	Hold	206	–	–	﹤0.01%	548
2018 Q4	$18K	Hold	206	–	–	﹤0.01%	560
2018 Q3	$20K	Hold	206	–	–	﹤0.01%	531
2018 Q2	$19K	Hold	206	–	–	﹤0.01%	559
2018 Q1	$17K	Hold	206	–	–	﹤0.01%	575
2017 Q4	$18K	Buy	+206	New	+$17.9K	﹤0.01%	603

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Covington Capital Management's BMRN Position: Q3 2022 in Review

Covington Capital Management held its BioMarin Pharmaceuticals (BMRN) position steady in Q3 2022 at 704 shares worth $60K. The position accounts for ﹤0.01% of the portfolio, ranked #536.

Covington Capital Management first reported a position in BMRN in Q4 2017 and has held it in 20 quarters since. 552 funds tracked by Wall St. Rank hold BMRN as of Q3 2022.

Covington Capital Management held 704 shares of BioMarin Pharmaceuticals worth $60K as of Q3 2022.
Covington Capital Management left its BioMarin Pharmaceuticals share count unchanged in Q3 2022.
BioMarin Pharmaceuticals made up ﹤0.01% of Covington Capital Management's portfolio in Q3 2022, its #536 holding.
Covington Capital Management first reported a position in BioMarin Pharmaceuticals in Q4 2017 and has held it in 20 quarters since.
552 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2022.

Based on Covington Capital Management's 13F filing for Q3 2022, filed 15 Nov 2022.